Your browser is no longer supported. Please, upgrade your browser.
Settings
BGNE BeiGene, Ltd. daily Stock Chart
BGNE [NASD]
BeiGene, Ltd.
Index- P/E- EPS (ttm)-18.69 Insider Own20.53% Shs Outstand77.33M Perf Week0.67%
Market Cap14.87B Forward P/E- EPS next Y-14.75 Insider Trans-0.70% Shs Float59.19M Perf Month14.70%
Income-1208.10M PEG- EPS next Q-4.77 Inst Own65.30% Short Float4.46% Perf Quarter40.53%
Sales402.40M P/S36.96 EPS this Y-39.00% Inst Trans0.73% Short Ratio11.57 Perf Half Y21.18%
Book/sh36.36 P/B5.41 EPS next Y16.80% ROA-47.20% Target Price199.40 Perf Year53.80%
Cash/sh44.63 P/C4.41 EPS next 5Y24.00% ROE-69.30% 52W Range114.41 - 210.35 Perf YTD18.68%
Dividend- P/FCF- EPS past 5Y- ROI-85.60% 52W High-4.87% Beta1.30
Dividend %- Quick Ratio7.90 Sales past 5Y101.10% Gross Margin82.60% 52W Low74.91% ATR6.62
Employees3600 Current Ratio8.00 Sales Q/Q-33.00% Oper. Margin- RSI (14)74.52 Volatility3.40% 3.75%
OptionableYes Debt/Eq0.09 EPS Q/Q-67.20% Profit Margin- Rel Volume1.74 Prev Close196.72
ShortableYes LT Debt/Eq0.09 Earnings- Payout- Avg Volume228.02K Price200.11
Recom1.90 SMA2010.24% SMA5018.46% SMA20024.27% Volume124,188 Change1.72%
Mar-13-20Upgrade Macquarie Underperform → Neutral
Feb-18-20Resumed Goldman Buy
Jan-17-20Upgrade CLSA Outperform → Buy
Jan-17-20Resumed Morgan Stanley Overweight $210
Dec-16-19Downgrade Piper Jaffray Overweight → Neutral
Dec-16-19Downgrade Guggenheim Buy → Neutral
Nov-19-19Downgrade UBS Buy → Neutral
Nov-13-19Downgrade CLSA Buy → Outperform
Nov-04-19Reiterated Maxim Group Buy $170 → $210
Jun-04-19Initiated Bernstein Outperform $201
May-10-19Upgrade CLSA Outperform → Buy
Mar-15-19Initiated BofA/Merrill Buy $200
Jan-04-19Downgrade CLSA Buy → Outperform
Nov-21-18Initiated JP Morgan Overweight $174
Sep-25-18Initiated Leerink Partners Outperform
May-17-18Reiterated Maxim Group Buy $200 → $225
May-14-18Initiated Credit Suisse Outperform
Apr-13-18Initiated Piper Jaffray Overweight $200
Apr-10-18Reiterated Maxim Group Buy $160 → $200
Mar-01-18Reiterated Maxim Group Buy $144 → $160
Jul-05-20 04:04PM  
Jul-02-20 07:00AM  
Jul-01-20 06:00PM  
08:12AM  
07:00AM  
Jun-30-20 07:30PM  
Jun-22-20 09:00AM  
Jun-19-20 12:27AM  
Jun-18-20 07:30AM  
Jun-12-20 02:30AM  
Jun-05-20 07:30AM  
Jun-03-20 07:15AM  
May-29-20 08:00AM  
08:00AM  
May-26-20 04:05PM  
04:04AM  
02:00AM  
May-21-20 07:00AM  
May-20-20 07:00AM  
May-15-20 07:00AM  
May-14-20 05:45PM  
09:00AM  
May-11-20 04:05PM  
Apr-29-20 05:00PM  
Apr-20-20 04:05PM  
Apr-13-20 04:05PM  
Apr-10-20 06:00PM  
Mar-26-20 02:30PM  
Mar-25-20 09:00AM  
Mar-19-20 05:09PM  
Mar-10-20 12:57PM  
Mar-09-20 12:30PM  
Mar-07-20 10:31AM  
Mar-02-20 04:05PM  
Feb-27-20 07:14AM  
Feb-25-20 07:00AM  
Feb-18-20 10:49AM  
Jan-21-20 07:00AM  
Jan-13-20 07:00AM  
Jan-08-20 07:30AM  
Jan-06-20 08:25AM  
Jan-03-20 02:11PM  
08:53AM  
Jan-02-20 08:15AM  
Dec-30-19 05:17PM  
Dec-28-19 09:30AM  
Dec-27-19 10:30PM  
Dec-22-19 06:00PM  
Dec-20-19 09:25AM  
Dec-19-19 04:40PM  
Dec-16-19 07:00AM  
Dec-13-19 07:00AM  
Dec-08-19 04:45PM  
Dec-02-19 06:02PM  
Nov-29-19 03:30PM  
Nov-26-19 05:54PM  
07:00AM  
Nov-23-19 05:00AM  
Nov-16-19 08:43AM  
Nov-15-19 05:34PM  
10:09AM  
04:30AM  
02:00AM  
Nov-14-19 04:20PM  
04:01PM  
03:49PM  
Nov-13-19 03:11PM  
Nov-12-19 04:05PM  
Nov-11-19 06:30PM  
Nov-10-19 07:00PM  
Nov-07-19 05:54PM  
Nov-06-19 10:58AM  
09:00AM  
Nov-05-19 10:13AM  
08:00AM  
Nov-04-19 11:18AM  
07:56AM  
Nov-01-19 06:12PM  
03:18PM  
02:49PM  
02:40PM  
07:38AM  
04:53AM  
03:01AM  
Oct-31-19 05:28PM  
04:00PM  
03:49PM  
07:54AM  
Oct-30-19 10:00AM  
Oct-29-19 08:02PM  
Oct-28-19 03:30PM  
Oct-23-19 04:50PM  
10:30AM  
Oct-18-19 03:35PM  
Oct-16-19 04:00PM  
Oct-15-19 05:13PM  
Oct-08-19 03:54PM  
Oct-07-19 08:05PM  
04:00PM  
Oct-01-19 07:19PM  
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; and Hutchison China MediTech Limited. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OYLER JOHNChief Executive OfficerJul 01Sale191.573,816731,0160Jul 01 04:43 PM
Wang XiaodongChair, Scientific Advisory BrdJul 01Sale190.754,847924,5720Jul 06 04:52 PM
Huang JaneCMO, HematologyJun 29Option Exercise29.491,50044,2351,500Jun 30 04:14 PM
OYLER JOHNChief Executive OfficerJun 29Sale192.601,435276,3740Jul 01 04:43 PM
Liang HowardCFO & Chief Strategy OfficerJun 29Sale191.2330057,3680Jul 01 04:38 PM
Huang JaneCMO, HematologyJun 29Sale190.831,935369,2500Jun 30 04:14 PM
Huang JaneCMO, HematologyJun 26Option Exercise160.402,079333,4722,079Jun 30 04:14 PM
Huang JaneCMO, HematologyJun 26Sale200.292,079416,3970Jun 30 04:14 PM
OYLER JOHNChief Executive OfficerJun 24Sale187.3414,3812,694,1560Jun 24 08:23 PM
Wang XiaodongChair, Scientific Advisory BrdJun 23Sale186.386,0001,118,2980Jun 24 08:12 PM
OYLER JOHNChief Executive OfficerJun 23Sale186.8815,0702,816,22214,381Jun 24 08:23 PM
OYLER JOHNChief Executive OfficerJun 22Sale182.4310,2811,875,60529,451Jun 24 08:23 PM
Wang XiaodongChair, Scientific Advisory BrdJun 22Sale181.335,000906,6730Jun 24 08:12 PM
OYLER JOHNChief Executive OfficerJun 10Sale175.07900157,5630Jun 12 04:14 PM
Liang HowardCFO & Chief Strategy OfficerJun 08Sale170.8445377,3910Jun 10 05:17 PM
Wu XiaobinPresident & GM ChinaJun 08Sale170.832,800478,3170Jun 10 05:15 PM
Huang JaneCMO, HematologyJun 08Sale170.84631107,8000Jun 10 05:13 PM
Wang XiaodongChair, Scientific Advisory BrdJun 08Sale170.916,0001,025,4550Jun 10 05:12 PM
Huang JaneCMO, HematologyMay 29Option Exercise29.491,50044,2351,500Jun 02 04:11 PM
Huang JaneCMO, HematologyMay 29Sale163.861,500245,7840Jun 02 04:11 PM
Glazer Donald W.DirectorMay 19Sale169.8410,0001,698,4000May 21 04:08 PM
OYLER JOHNChief Executive OfficerMay 01Sale141.434,635655,5370May 05 04:48 PM
Wu XiaobinPresident & GM ChinaMay 01Sale141.337,024992,7110May 05 04:46 PM
Huang JaneCMO, HematologyApr 29Option Exercise29.491,50044,2351,500Apr 30 04:04 PM
Huang JaneCMO, HematologyApr 29Sale162.301,500243,4500Apr 30 04:04 PM
Huang JaneCMO, HematologyApr 16Option Exercise29.491,50044,2351,500Apr 17 04:04 PM
Huang JaneCMO, HematologyApr 16Sale160.001,500240,0000Apr 17 04:04 PM
Wang XiaodongChair, Scientific Advisory BrdMar 04Sale157.145,000785,6810Mar 06 08:30 PM
Huang JaneCMO, HematologyFeb 18Option Exercise29.491,50044,2351,500Feb 20 04:13 PM
Huang JaneCMO, HematologyFeb 18Sale170.251,500255,3800Feb 20 04:13 PM
Huang JaneCMO, HematologyJan 21Option Exercise29.491,50044,2351,500Jan 22 06:59 PM
Huang JaneCMO, HematologyJan 21Sale170.691,500256,0420Jan 22 06:59 PM
OYLER JOHNChief Executive OfficerDec 17Sale160.6262,25910,000,1000Dec 19 04:10 PM
Huang JaneCMO, HematologyDec 16Option Exercise29.491,50044,2351,500Dec 18 06:57 PM
Huang JaneCMO, HematologyDec 16Sale165.141,500247,7100Dec 18 06:57 PM
Huang JaneCMO, HematologyNov 18Option Exercise29.491,50044,2351,500Nov 20 07:19 PM
Liang HowardCFO & Chief Strategy OfficerNov 18Option Exercise6.5025,000162,50025,000Nov 20 07:20 PM
Liang HowardCFO & Chief Strategy OfficerNov 18Sale194.3425,0004,858,6160Nov 20 07:20 PM
Huang JaneCMO, HematologyNov 18Sale194.491,500291,7400Nov 20 07:19 PM
Wu XiaobinPresident & GM ChinaNov 15Sale202.051,000202,0500Nov 18 05:22 PM
Wang XiaodongChair, Scientific Advisory BrdNov 15Sale202.0539579,8100Nov 18 05:24 PM
Wang XiaodongChair, Scientific Advisory BrdNov 15Sale202.051,496302,2670Nov 18 05:24 PM
Wang XiaodongChair, Scientific Advisory BrdNov 14Sale193.572,605504,242395Nov 18 05:24 PM
Wang XiaodongChair, Scientific Advisory BrdNov 14Sale193.318,5041,643,8801,496Nov 18 05:24 PM
Chen Timothy Yung-ChengDirectorNov 05Option Exercise41.014,000164,0404,000Nov 06 06:50 PM
Chen Timothy Yung-ChengDirectorNov 05Sale189.153,800718,772200Nov 06 06:50 PM
Huang JaneCMO, HematologyNov 04Option Exercise29.4932,900970,22132,900Nov 06 06:51 PM
Chen Timothy Yung-ChengDirectorNov 04Option Exercise41.014,000164,0404,000Nov 06 06:50 PM
Huang JaneCMO, HematologyNov 04Sale190.4632,9006,266,0070Nov 06 06:51 PM
Chen Timothy Yung-ChengDirectorNov 04Sale190.494,200800,0730Nov 06 06:50 PM
Wang XiaodongChair, Scientific Advisory BrdNov 04Sale190.001,000190,0000Nov 05 04:22 PM
Wang XiaodongChair, Scientific Advisory BrdNov 01Sale170.001,000170,0000Nov 05 04:22 PM
Wu XiaobinPresident & GM ChinaNov 01Sale180.001,000180,0000Nov 05 04:20 PM
Huang JaneCMO, HematologySep 04Sale129.408210,6110Sep 05 08:15 PM
Huang JaneCMO, HematologySep 03Sale144.452,862413,4200Sep 05 08:15 PM
Chen Timothy Yung-ChengDirectorAug 23Option Exercise31.597,900249,5617,900Aug 27 04:04 PM
Chen Timothy Yung-ChengDirectorAug 23Sale144.968,6141,248,6800Aug 27 04:04 PM
Huang JaneCMO, HematologyAug 12Option Exercise45.312,500113,2752,500Aug 13 04:47 PM
Huang JaneCMO, HematologyAug 12Sale134.742,500336,8550Aug 13 04:47 PM
Huang JaneCMO, HematologyJul 29Option Exercise37.3010,130377,83410,130Jul 31 04:04 PM
Huang JaneCMO, HematologyJul 29Sale134.5410,1301,362,8960Jul 31 04:04 PM
OYLER JOHNChief Executive OfficerJul 08Sale126.873,106394,0550Jul 09 07:23 PM